Acetylcholinesterase (AChE)

Overview

Acetylcholinesterase (AChE; EC 3.1.1.7) is a serine hydrolase enzyme that catalyzes the rapid breakdown of the neurotransmitter acetylcholine into choline and acetate, terminating cholinergic signaling at synapses and neuromuscular junctions. Its catalytic machinery sits at the base of a deep, narrow active-site gorge lined by aromatic residues, with a catalytic triad at one end and a peripheral anionic site at the gorge mouth — an architecture that gives the enzyme both extraordinary turnover speed and two spatially distinct pockets that inhibitors can be designed to occupy. The protein is expressed in cholinergic neurons, at motor endplates, and on erythrocyte membranes, where it also carries the Yt blood group antigen; red blood cell AChE activity is used clinically as a marker of cholinesterase status. Beyond hydrolysis, AChE has been implicated in non-catalytic roles including cell adhesion, neurite outgrowth, and responses to oxidative stress and apoptotic signaling.

Pharmacologically, AChE is a central drug target. Inhibiting it raises synaptic acetylcholine levels, the mechanism behind cholinergic therapy for Alzheimer's disease with agents such as donepezil, and much current medicinal chemistry — coumarin carboxamides, flavonoids and biflavonoids, and other plant-derived scaffolds such as chrysin, apigenin, naringenin, hesperidin, and rosmarinic acid — is screened for AChE inhibition alongside the closely related butyrylcholinesterase, which hydrolyzes a broader range of esters and becomes proportionally more important as AChE activity declines in the aging brain. Because such compounds must reach the central nervous system, blood–brain barrier permeability is a routine consideration in their evaluation, often alongside docking, molecular dynamics, and QSAR modeling. AChE inhibition is frequently studied together with other Alzheimer's-relevant targets including beta-secretase 1, glycogen synthase kinase 3β, and amyloid beta, and with markers of oxidative stress and neuroinflammation such as superoxide dismutase, catalase, glutathione, reactive oxygen species, TNF-α, IL-1β, and COX-2 — a combination that links AChE to work on diabetes-associated neurodegeneration, where insulin resistance and hyperglycemia accompany cholinergic and hippocampal damage and where dual-acting agents such as SGLT2 inhibitors have been examined. Conversely, irreversible inhibition of AChE by organophosphate pesticides and nerve agents causes acetylcholine accumulation and the cholinergic toxidrome, and the enzyme's sensitivity to these compounds is itself exploited in biosensors that detect organophosphate residues.

Recent Publications Summary (latest 30 papers)

Recent studies continue to establish acetylcholinesterase (AChE) as a pivotal therapeutic target in neurodegenerative diseases, particularly Alzheimer's disease, with research spanning natural product screening, synthetic inhibitor design, and novel diagnostic applications. The enzyme remains central to reversing cholinergic dysfunction in cognitive decline, and mounting evidence supports multitarget approaches combining AChE inhibition with complementary neuroprotective mechanisms.

Natural products have yielded potent AChE inhibitors from diverse plant sources. Polymethoxylated flavones isolated from Knema malayana leaves demonstrated dual inhibitory activity, with compound 2 achieving an AChE IC₅₀ of 10.2 μM 42563004Aug. Echinocactus grusonii spines exhibited notably stronger inhibition (IC₅₀ 0.362 µg/mL), exceeding the associated endophytic fungus Aspergillus oryzae (IC₅₀ 0.255 µg/mL) 42527432Jul. Biflavonoids from Encephalartos species—amentoflavone, bilobetin, and ginkgetin isolated from E. ferox—showed AChE IC₅₀ values ranging from 0.762 to 2.146 µg/mL, surpassing rivastigmine 42443245Jul. Herbal extracts from Andrographis paniculata and Salvia heldreichiana exhibited measurable AChE inhibition, with rosmarinic acid and chrysin demonstrating strong computational binding to enzyme active sites 42250615Jun42220228Jun. In disease models, polydatin showed in silico inhibitory activity against AChE in diabetic rats 42423809Jul, and trans-anethole offered neuroprotection against aluminum-induced memory impairment via AChE targeting 42154340May.

Synthetic development has yielded inhibitors of exceptional potency. Coumarin-3-carboxamide derivatives CM4 and CM8 displayed AChE IC₅₀ values of 19.04 nM and 17.73 nM, respectively—significantly surpassing donepezil (27.27 nM) 42481895Jul. Tacrine derivatives with soluble epoxide hydrolase inhibition (compound Z43) achieved 1.7 nM AChE IC₅₀ while maintaining favorable pharmacokinetics and blood-brain barrier penetration 42013744Apr. Chiral urea and thiourea derivatives demonstrated multitarget inhibition of AChE and monoamine oxidase B at nanomolar concentrations 42403010Jul. Quinazolin-4-one-based chalcones and coumarin-benzothiazole hybrids achieved dual AChE/butyrylcholinesterase inhibition (AChE IC₅₀ 0.751 µg/mL), addressing cholinergic depletion across disease stages 42149153May41965189Apr. Phenylsulfonylethyl-substituted benzimidazolium salts and chiral anthranilic diamides expanded the inhibitor repertoire with nanomolar-level potency and favorable physicochemical profiles 42502223Jul42050895Apr.

Therapeutic applications now extend beyond single-target inhibition toward integrated disease-modifying strategies. Tacrine-based dual AChE/epidermal growth factor receptor inhibitors (S24-1008, S24-1017) provided neuroprotection against oxidative and excitotoxic stressors with demonstrated cognitive benefits in scopolamine-induced models 42107267May. Canagliflozin, a dual sodium-glucose transporter 2 and AChE inhibitor, reversed hippocampal dendritic pathology in streptozotocin-induced Alzheimer's models 42289507Jun. Lawsone and natural compounds including daurioxoisoporphine D demonstrated multifactorial activity targeting AChE alongside amyloid-beta aggregation and neuroinflammatory pathways in cognitively-impaired rodent models 42105996May42008955Apr.

Emerging diagnostic applications have positioned AChE as both a drug target and a quantifiable biomarker. A metal-organic framework biosensor (ZIF8@MIL101(Al)) with AgAu nanoclusters enabled ultrasensitive AChE detection (limit of detection 0.032 U L⁻¹) and simultaneous inhibitor drug screening in serum 42411317Jul. A d-band-modulated Au@RuPt nanozyme enabled organophosphate pesticide detection through AChE-mediated oxygen reduction reaction poisoning at levels as low as 0.0264 ng mL⁻¹ 42384538Jul. Organic photoelectrochemical transistor sensors achieved reusable, multienzyme-cascade detection of AChE activity and its inhibition 42093401May. A chemiluminescent AChE-responsive probe identified hypoxia-induced brain injury in acute ischemic stroke models with 3–23-fold signal enhancement, establishing AChE as a viable imaging biomarker 42118815May. Quantitative structure-activity relationship modeling via the open-source RANQSAR platform standardized inhibitor discovery workflows, advancing reproducible computational drug development 42390765Jul.

What Changes, What Holds

1. Multitarget strategies combining AChE inhibition with neuroprotective mechanisms gain mounting empirical support
REINFORCES Mounting evidence supports multitarget approaches integrating AChE inhibition with complementary neuroprotective mechanisms, natural product screening, and synthetic inhibitor design. The Overview already identifies such strategies as central to current research. Paragraph [1] reaffirms this research direction without introducing novel mechanisms, targets, or unexpected synergies. This reinforces established approaches rather than expanding understanding of AChE's roles or disease-modifying potential.

2. Plant-derived compounds from diverse sources achieve AChE inhibition potency comparable to or exceeding established cholinesterase reference drugs
REINFORCES Multiple plant sources—Knema malayana, Echinocactus grusonii, Encephalartos species, and others—yield inhibitors with potency benchmarked against rivastigmine 42527432Jul42443245Jul. The Overview already identifies plant-derived scaffolds as a current research focus. The new work exemplifies this class with measured IC₅₀ values but does not change what is understood about the plant-screening strategy or its role in AChE inhibitor discovery. This reinforces an established medicinal chemistry approach.

3. Synthetic AChE inhibitors now routinely achieve nanomolar potency, with lead compounds surpassing donepezil's affinity
REINFORCES Coumarin-3-carboxamides and tacrine derivatives achieve IC₅₀ values of 17.73–19.04 nM and as low as 1.7 nM 42481895Jul42013744Apr, exceeding donepezil (27.27 nM). The Overview identifies coumarin carboxamides as a current research direction but does not specify potency limits. Superior in vitro potency without clinical efficacy data does not alter the established role of synthetic chemistry in drug screening. These results exemplify refinement of an existing approach, not expansion into new mechanisms.

4. Integrated molecular agents targeting AChE and complementary pathways demonstrate neuroprotection and cognitive improvement in disease models
REINFORCES Tacrine-EGFR dual inhibitors and canagliflozin (SGLT2/AChE) reverse pathology and restore cognition in scopolamine-induced and diabetic neurodegenerative models 42107267May42289507Jun. The Overview already discusses multitarget research and SGLT2 inhibitor examination in diabetes-associated neurodegeneration. Paragraph [4] validates this strategy with preclinical efficacy data but does not introduce unexpected synergies or shift away from multitarget research. This reinforces the established multitarget approach.

5. AChE dynamics now serve as an imaging biomarker for acute cerebral injury, expanding diagnostic roles beyond toxin exposure assessment
NEW DIRECTION Chemiluminescent AChE-responsive probes detect hypoxia-induced brain damage in ischemic stroke with 3–23-fold signal enhancement, identifying AChE as a pathology indicator 42118815May. The Overview recognizes AChE as a marker for cholinesterase status and in biosensors for organophosphate detection. Using AChE alterations to image acute CNS injury represents a distinct clinical application absent from the baseline. Metal-organic framework and nanozyme biosensors represent technological refinement 42411317Jul; RANQSAR provides computational methodology advancement. The stroke imaging biomarker is the substantive addition.

Overview update candidates: AChE as a neuroimaging biomarker for acute ischemic stroke (42118815May).